llms.blog
AI

QuantHealth raises $45M to simulate clinical trials before patients enroll

QuantHealth, a Tel Aviv startup, has raised forty five million dollars in Series B funding to grow its clinical trial simulation platform. Qumra Capital led the round, and the company says total funding now stands near seventy million dollars since its 2020 founding. The pitch is simple to state and hard to achieve: test a trial in software before a single patient is recruited. QuantHealth's tools let drug developers model whether a protocol is likely to succeed, tune who gets included, and est

axc
axc
1 min
QuantHealth raises $45M to simulate clinical trials before patients enroll

QuantHealth, a Tel Aviv startup, has raised forty five million dollars in Series B funding to grow its clinical trial simulation platform. Qumra Capital led the round, and the company says total funding now stands near seventy million dollars since its 2020 founding.

Scientists running a virtual clinical trial simulation before patients enroll

The pitch is simple to state and hard to achieve: test a trial in software before a single patient is recruited. QuantHealth's tools let drug developers model whether a protocol is likely to succeed, tune who gets included, and estimate commercial outcomes in silico. The company says its predictions are already used inside twelve of the top twenty global pharmaceutical firms.

Why it matters: most candidates that enter human testing fail. The industry's trial failure rate sits around ninety percent, and each miss burns years of work and millions of dollars. A simulation layer that flags weak designs earlier could shrink that waste and push proven drugs to market faster.

The platform draws on large real world datasets and predictive analytics across more than thirty therapeutic areas, including oncology, cardiometabolic disease, and inflammatory conditions. QuantHealth reports up to ninety percent predictive accuracy across more than six hundred simulated trials.

The new capital is earmarked for next generation AI models, broader disease coverage, more scientific validation, and a larger go to market team. Other participants in the round include Pitango HealthTech, Sanofi Ventures, Bertelsmann Healthcare Investments, and several health focused venture funds.

Sources

Techmeme (aggregating Fierce Healthcare): https://www.techmeme.com/260809/p11#a260809p11

MedCity News: https://medcitynews.com/2026/08/quanthealth-ai-drug-discovery

MobiHealth News: https://www.mobihealthnews.com/news/quanthealth-lands-45m-ai-clinical-trial-simulations

HitConsultant: https://hitconsultant.net/2026/08/04/beyond-real-world-trial-iteration-quanthealth-secures-45m-for-ai-clinical-simulation

AIHealthcareStartups
ShareX (Twitter)LinkedIn

Written by

axc

More to read

  • Discrete Diffusion in Large Language Models: How Continuous-Time Markov Chains, Absorbing States, and Score Entropy Challenge Autoregressive Generation

    The dominance of autoregressive architectures in large language models rests on a fundamental mathematical formulation: the chain rule of probability. By factoring the joint distribution of a sequence into a product of conditional probabilities, $p(x) = \prod_{i=1}^N p(x_i \mid x_{<i})$, autoregressive models reduce text generation to sequential next-token prediction. While this left-to-right causal factorization has scaled effectively across compute regimes, it imposes rigid operational constr

    1 min

  • AI Agents Surpass Humans on OpenRouter as Agentic Token Usage Jumps 14x

    Autonomous AI agents have overtaken human users as the primary consumers of language model compute on OpenRouter, with agentic token volume surging fourteenfold over the past six months. Data published by OpenRouter analyst Peter Walker indicates that February 6 marked the permanent inflection point where token consumption by automated agents exceeded direct human API traffic. Since that threshold, agentic token volume on the multi-model gateway has climbed from 0.51 trillion to 7.3 trillion to

    1 min

  • Continuous Pre-Training in Production: Domain Adaptation, Replay Buffers, Learning Rate Restarts, and Catastrophic Forgetting Mitigation

    Continuous Pre-Training in Production: Domain Adaptation, Replay Buffers, Learning Rate Restarts, and Catastrophic Forgetting Mitigation Adapting general-purpose foundation models to specialized enterprise domains (such as clinical medicine, corporate law, quantitative finance, and proprietary software codebases) presents a fundamental architectural challenge. While Retrieval-Augmented Generation (RAG) and Supervised Fine-Tuning (SFT) remain standard first-line approaches, both exhibit severe s

    1 min